MBRX MOLECULIN BIOTECH INC revenue, earnings and financials
For the quarter ended June 30, 2026, MOLECULIN BIOTECH INC reported revenue of $0, net income of −$7.64M and diluted EPS of n/a; over the last four quarters revenue was $0 and net income $36.8M; for the fiscal year ended December 2025 revenue was $0.
MBRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$25.1M, net income $33.6M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$26.6M, net income $26.0M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$29.6M, net income $29.8M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$30.6M, net income −$29.0M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$23.0M, net income −$15.9M (margin n/a), EPS −$0.59
MBRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$7.64M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $0, net income −$12.8M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income $82.7M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $0, net income −$25.4M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$17.8M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $0, net income −$5.90M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income $45.5M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$7.02M, EPS n/a
- Quarter ended Jun 30, 2024: revenue $0, net income −$6.02M, EPS n/a
- Quarter ended Mar 31, 2024: revenue $0, net income −$6.43M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income $49.3M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$5.61M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $0, net income −$5.98M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $0, net income −$7.92M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$6.77M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $0, net income −$8.61M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $0, net income −$6.78M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $0, net income −$6.87M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$2.83M, EPS −$0.09
- Quarter ended Sep 30, 2021: revenue $0, net income −$4.38M, EPS −$0.15
MBRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$22.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$23.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$27.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$19.0M, share buybacks n/a
MBRX balance sheet
- Jun 30, 2026: cash $7.26M, total assets $21.1M, total liabilities $9.50M, shareholders' equity $11.6M
- Mar 31, 2026: cash $10.3M, total assets $23.4M, total liabilities $8.18M, shareholders' equity $15.2M
- Dec 31, 2025: cash $8.88M, total assets $22.1M, total liabilities $7.12M, shareholders' equity $15.0M
- Sep 30, 2025: cash $6.70M, total assets $20.4M, total liabilities $47.3M, shareholders' equity −$26.9M
- Jun 30, 2025: cash $7.56M, total assets $21.6M, total liabilities $25.2M, shareholders' equity −$3.59K
- Mar 31, 2025: cash $7.72M, total assets $21.0M, total liabilities $7.22M, shareholders' equity $13.8M
- Dec 31, 2024: cash $4.28M, total assets $16.9M, total liabilities $5.72M, shareholders' equity $11.2M
- Sep 30, 2024: cash $9.41M, total assets $23.4M, total liabilities $15.9M, shareholders' equity $17.4M
What is MBRX's revenue?
MOLECULIN BIOTECH INC reported $0 of revenue over its last four quarters, through June 30, 2026.
Is MBRX profitable?
Yes. MOLECULIN BIOTECH INC earned $36.8M over the last four quarters.